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Abstract
Background: Hepatic and peritoneal metastases of gastric cancer are operation contraindications. Systematic review
to provide an overview of imaging in predicting the status of liver and peritoneum pre-therapeuticly is essential.
Methods: A systematic review of relevant literatures was performed in Pubmed/Medline, Embase, The Cochrane
Library and the China Biological Medicine Databases. QUADAS was used for assessing the methodological quality
of included studies and the bivariate model was used for this meta-analysis.
Results: Totally 33 studies were included (8 US studies, 5 EUS studies, 22 CT studies, 2 MRI studies and 5 18F-FDG
PET studies) and the methodological quality of included studies was moderate. The result of meta-analysis showed
that CT is the most sensitive imaging method [0.74 (95% CI: 0.59-0.85)] with a high rate of specificity [0.99 (95% CI:
0.97-1.00)] in detecting hepatic metastasis, and EUS is the most sensitive imaging modality [0.34 (95% CI: 0.10-0.69)]
with a specificity of 0.96 (95% CI: 0.87-0.99) in detecting peritoneal metastasis. Only two eligible MRI studies were
identified and the data were not combined. The two studies found that MRI had both high sensitivity and specificity
in detecting liver metastasis.
Conclusion: US, EUS, CT and
18F-FDG PET did not obtain consistently high sensitivity and specificity in assessing
liver and peritoneal metastases of gastric cancer. The value of laparoscopy, PET/CT, DW-MRI, and new PET tracers
such as
18F-FLT needs to be studied in future.
Background
Although the decreasing incidence and mortality, gastric
cancer remains the fourth common cancer and the sec-
ond leading cause of cancer-related deaths with poor
prognosis worldwide [1,2]. As we known, treatment
option, decision-making and prognosis of gastric cancer
are strongly dependent on the extent of tumor (tumor
extension, nodal involvement and distant metastases),
accurately pretherapeutic staging is essential [3].
It was reported that the rate of liver metastasis in gastric
cancer can achieve 5-9% [4,5], and the number of liver
metastasis is a significant prognostic factor of gastric
cancer [4,6]. Generally speaking, gastric cancer has extra-
hepatic metastasis if hepatic metastasis, such as lymph
node involvement and peritoneal seeding. Surgical resec-
tion is rarely required under these circumstances [5]. Peri-
toneal metastasis, mainly induced by the dissemination of
free tumor cells from the primary gastric cancer, is one of
the most common types of spread and the causes of death
[7]. Peritoneal metastasis of gastric cancer was considered
to be operation contraindication and the most difficult
type for treatment [8].
Studies suggested that imaging methods of evaluating
the pre-operative status of hepatic and peritoneal metas-
tases have two effects [9,10]: 1) avoiding unnecessary
laparotomy; 2) assessing the effectiveness of neoadjuvant
protocols in the absence of histopathological confirma-
tion. Although systematic review and meta-analysis of
imaging in assessing local staging and lymph node status
of gastric cancer were performed [11,12], there is no con-
sensus on the most sensitive imaging method for detect-
ing hepatic and peritoneal metastases of gastric cancer
now. Theoretically pre-operative staging of gastric cancer
should mainly focus on assessing distant metastases but
not local staging or lymph node status, since if one
patient has distant metastases, an exploratory laparotomy
always can be avoided [13].
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comprehensive and up-to-date overview of sensitivity
and specificity of imaging [ultrasonography(US), Endo-
scopic ultrasound(EUS), computed tomography (CT),
magnetic resonance imaging(MRI), and
18F-fluorodeoxy-
glucose positron emission tomography(
18F-FDG PET)]
in detecting hepatic and peritoneal metastases of gastric
cancer.
Methods
Search strategy
A computer-aided search of the Pubmed/Medline,
Embase, The Cochrane Library (issue 1, 2011), and the
China Biological Medicine Database (CBM) was con-
ducted to identify relevant publications on the diagnos-
tic performance of imaging (US, EUS, CT, MRI, and
18F-FDG PET) in detecting hepatic and peritoneal
metastases of gastric cancer. The upper limit of search
date was not limited, and the lower limit was February,
2011. The following search phrases were used: stomach
neoplasms, stomach cancer, stomach carcinoma, sto-
mach tumor, gastric cancer, gastric carcinoma, gastric
neoplasms, gastric tumor, liver metastasis/metastases,
hepatic metastasis/metastases, peritoneal metastasis/
metastases, peritoneal seeding, peritoneal involvement,
peritoneal carcinomatosis, sensitivity, specificity, accu-
racy. Both free text and MeSH search for keywords
were employed. The language was not limited. To
search more potentially relevant trials, reference lists
from included studies of electronic searching were
screened.
Inclusion and exclusion criteria
Inclusion criteria for this meta-analysis
1. Studies assessed the diagnostic value of imaging
(US, EUS, CT, MRI, or
18F-FDG PET) in detecting
hepatic or peritoneal metastasis of gastric cancer.
2. The standard of reference had to be a surgery or
histopathological examination.
3. True-positive, false-positive, true-negative, and
false-negative results of imaging methods could be
calculated for per-patient.
4. PET had to be performed with intravenous
administration of
18F-FDG.
Exclusion criteria for this meta-analysis
1. Studies included patients with non-adenocarci-
noma (eg, lymphoma).
2. Studies only assessed gastric cancer confined to a
specific part of the stomach (eg, cardia or gastroeso-
phageal junction), which could not represent overall
place where tumour may occur.
3. Studies included patients who received radiother-
apy or chemotherapy pre-operatively, which may
cause downstaging. (Because neoadjuvant protocols
can lead to tumor downstaging and affect the diag-
nostic accuracy of imaging)
4. Vitro studies and studies performed in animals.
5. Studies with a sample size less than 10.
6. Studies were not original research (eg, systematic
review)
Study selection was performed by two authors
(Z. Wang and J.Q.Chen) independently according to the
inclusion and exclusion criteria. When we found eligible
studies with published data more than once, we only
included the article with the most patients. Disagree-
ments were resolved by consensus.
Data extraction and quality assessment
Two authors (Z. Wang and J.Q.Chen) extracted data
using pre-defined tables, which included items as fol-
lows: author and publication time, country of source,
sample size, interpreters, standard reference, image
modality (US, EUS, CT, MRI, or
18F-FDG PET), imaging
technique (transducer frequency for US and EUS; use of
intravenous contrast, section thickness and gap for CT;
use of intravenous contrast, section thickness, gap, field
strength and coil type for MRI; time of fasting before
scanning, FDG dose, time interval between FDG admin-
istration and scanning, attenuation correction, and
reconstruction method for
18F-FDG PET) and test result
(true positive, false positive, true negative and false
negative on per patient basis).
Fourteen items of QUADAS were used to assess the
methodological quality of eligible studies [14]. Descrip-
tions of each item: Yes (score 2); Unclear (score 1); No
(score 0). Total quality score was the summary score of
each item. We consider that studies with a total score
more than 17 were regarded as high methodological
quality, and less than 17 as low methodological quality.
Data analysis
Pooled estimates of sensitivity, specificity and diagnostic
odds ratio (DOR) of imaging (with corresponding 95%
confidence intervals [CIs]) were analyzed based on the
bivariate model [15]. The bivariate model uses a random
effect approach for both sensitivity and specificity,
which allows for heterogeneity beyond chance as a
result of clinical and methodological differences between
studies, and the bivariate model is considered as a more
valid statistical model for diagnostic meta-analysis
[16,17]. To graphically present the results, we plotted
the hierarchical summary receiver operating characteris-
tic (HSROC) curves [16]. As a potential cause of hetero-
geneity in sensitivity and specificity among the included
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Spearman correlation coefficient between the logit of
sensitivity and logit of 1-specificity; heterogeneity
induced by factors other than threshold/cut off effect
was assessed by using the Cochran Q statistic (c
2 test).
Statistical significance of heterogeneity test was assumed
when a P value was less than 0.10. As a concern for
meta-analysis of diagnostic trials, publication bias was
tested using the funnel plot and Deeks test [18], which
was conducted by a regression of diagnostic log odds
ratio against 1/sqrt(effective sample size), weighting by
effective sample size, with P < 0.10 for the slope coeffi-
cient indicating significant asymmetry. Meta-Disc (ver-
sion 1.4), Stata (version 11.0), especially the midas and
metandi commands were used for statistical analysis
[19,20] (Appendix).
Results
Study selection and description
According to the pre-defined search strategy, total 1310
literatures were revealed: 449 from Pubmed/Medline,
853 from Embase, 0 from the Cochrane Library and 8
from CBM. By screening the tittles and abstracts we
found that lots of articles were irrelevant and some were
identified in more than one database, thus 101 studies
remained for potential inclusion and were obtained in
full-text version. After reviewing the full text, 68 studies
were excluded. The mainly reasons for excluded studies
were as follows: non-original research(eg. review arti-
cles), not reporting the diagnostic performance of liver
or peritoneal metastasis, insufficient data to construct a
2 × 2 contingency table, inclusion of patients with non-
adenocarcinoma, gastric carcinoma confined to a speci-
fic part of the stomach or included patients received
neoadjuvant chemotherapy. At last 33 studies [21-53]
were included (8 US studies, 5 EUS studies, 22 CT stu-
dies, 2 MRI studies and 5
18F-FDG PET studies). The
process of study selection was listed in Figure 1.
The 8 US studies were published between 1983 and
2004, and the sample size varied from 21 to 125 (Table 1).
The 5 EUS studies were published between 1990 and
2005, and the sample size ranged from 48 to 402
(Table 2). The 22 CT studies were published between
1994 and 2010, and the sample size varied from 36 to 640
(Table 3). The 2 MRI studies were published between
2006 and 2007, and the sample size varied from 25 to 35
(Table 4). The 5
18F-FDG PET studies were published
between 1998 and 2006, and the sample size varied from
23 to 124. Among the 5
18F-FDG PET studies, one study
[35] used two kinds of scanners (PT931/04 scanner and
SET2400W scanner), and we analyzed the data separatedly
according to the kind of scanner (Table 5).
The quality of included studies was assessed based on
the 14 items of QUADAS (Table 6). The total score
varied from 14 to 22 in US studies, 17 to 25 in EUS stu-
d i e s ,1 4t o2 3i nC Ts t u d i e s ,1 5t o1 9i nM R Is t u d i e s ,
and 16 to 21 in
18F-FDG PET studies.
Results of meta-analysis
Heterogeneity tests
Table 7 presented the Spearman correlation coefficient
for each test. The p value was larger than 0.1 except for
EUS in the detection of peritoneal metastasis.
Table 8 presented the results of Cochrane-Q test. For
EUS in the detection of peritoneal metastasis, Cochrane-Q
test failed to be conducted using the metandi command in
stata software due to unstability. Except for US and PET
in the detection of peritoneal metastasis, the p value of
Cochrane-Q test was less than 0.1, which suggested signif-
icant heterogeneity between included studies.
Diagnostic value
Liver metastasis
The data were available in 8 US studies [21-27,29], 2 EUS
studies [27,31], 18 CT studies [21-23,27,29,36,39,
41,43-51,53], 2 MRI studies [37,38], and 4
18F-FDG
PET studies [35,36,41,42]. Meta-analysis was based on the
bivariate model in the presence of significant heterogeneity.
Pooled sensitivity for US, CT and
18F-FDG PET in
detecting liver metastasis were 0.54 (95% CI: 0.34-0.73),
0.74 (95% CI: 0.59-0.85) and 0.70 (95% CI: 0.36-0.90)
respectively (Table 9).
Pooled specificity for US, CT and
18F-FDG PET in
detecting liver metastasis were 0.98 (95% CI: 0.90-0.99),
0.99 (95% CI: 0.97-1.00) and 0.96 (95% CI: 0.81-0.99),
respectively. (Table 9)
Pooled DOR for US, CT and 18F-FDG PET in detect-
ing liver metastasis were 50.25 (95% CI: 13.48-187.32),
251.14 (95% CI: 83.53-755.07) and 56.46 (95% CI: 8.47-
376.23) respectively (Table 9).
Only two studies’ data were sufficient for EUS and
MRI, and we did not conduct pooled analysis, but pre-
sented the result of each study in Table 10.
Peritoneal metastasis
The data were available in 5 US studies [21-23,25,29],
4 EUS studies [30-33], 15 CT studies [21,22,29,34,
36,39,40,43-48,52,53] and 4
18F-FDG PET studies
[34-36,42]. Meta-analysis was based on the bivariate
model in the presence of significant heterogeneity.
Pooled sensitivity for US, EUS, CT and
18F-FDG PET
in detecting peritoneal metastasis were 0.09 (95% CI:
0.03-0.21), 0.34 (95% CI: 0.10-0.69), 0.33 (95% CI: 0.16-
0.56) and 0.28 (95% CI: 0.17-0.44) respectively (Table 9).
Pooled specificity for US, EUS, CT and
18F-FDG PET
in detecting peritoneal metastasis were 0.99 (95% CI:
0.96-1.00), 0.96 (95% CI: 0.87-0.99), 0.99 (95% CI:
0.98-1.00) and 0.97 (95% CI: 0.83-1.00), respectively
(Table 9).
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Potential full texts for included N=101 
Non-original research N=10; 
Not reporting the diagnostic performance of liver or peritoneal 
metastasis N=29; 
Insufficient data N=11; 
Included patients with non-adenocarcinoma N= 6; 
Included patients with gastric carcinoma confined to a specific part 
of the stomach N=11 
Included patients received neoadjuvant chemotherapy N=1 
Irrelevant tittles and abstracts, and repetitive 
presence in more than database N=1209 
Eligible studies N=33 
US studies 
 N=8 
EUS studies 
N=5 
CT studies 
N=22 
MRI studies 
N=2 
18F-FDG PET 
studies N=5 
Figure 1 QUORUM flow chart for including studies.
Table 1 Characteristics of the eight included US studies
Study
(year, reference)
County No. of
patients
Transducer
frequency
(MHz)
Interpreter(s) Reference standard
Kim 1997 [21] South
Korea
95 3.5 or 5 Two radiologists independently Surgical and pathological findings
Stell 1996 [22] United
Kingdom
103 3.5 Experienced personnel Histological examination
Asencio 1997 [23] Germany 71 NCD NCD Surgical and histologic
evaluation
Possik 1986 [24] United
States
82 NCD NCD Surgical and histologic evaluation
Derchi 1983 [25] United
States
21 3.5 Two authors of the study Surgical and pathological examization.
Liao 2004 [26] China 125 3.5 or 6.0 NCD Operative and pathological examination
Ozmen 2003 [27] United
States
48 NCD NCD Histological examination
Kayaalp 2002 [28] United
Kingdom
118 NCD A consultant radiologist Histopathological examinations
NCD: not clearly described.
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18F-FDG PET in
detecting peritoneal metastasis were 10.63 (95% CI:
1.54-73.36), 13.07 (95% CI: 6.42-26.62), 66.18 (95% CI:
27.28-160.53) and 12.49 (95% CI: 2.22-70.10), respec-
tively (Table 9).
HSROC curves
We plotted HSROC curves to graphically present the
results (Figure 2, 3, 4, 5, 6, 7, 8). In HSROC curves, the
index test’s sensitivity (true positive rate) was plotted on
the y axis against 1-specificity (false negative rate) on
the x axis. In addition, the 95% confidence region and a
95% prediction region around the pooled estimates were
plotted to illustrate the precision with which the pooled
values were estimated (confidence ellipse of a mean)
and to show the amount of between study variation
(prediction ellipse; the likely range of values for a new
study) [16].
Publication bias
Because the number of included studies was few, we
only explored publication bias using the data of CT in
detecting liver metastasis, which included 18 studies. As
a result, the funnel plot seemed symmetrical with a
P value of 0.66, and this suggested a low risk of publica-
tion bias (Figure 9).
Discussion
As far as we know, this systematic review is the first
study that evaluates the summary estimates of sensitivity
and specificity of five imaging modalities which are cur-
rently used for the detection of hepatic and peritoneal
metastases. The pooled result basing on the bivariate
model showed that CT is the most sensitive imaging
method [0.74 (95% CI: 0.59-0.85)] with a high rate of
specificity [0.99 (95% CI: 0.97-1.00)] in detecting hepatic
metastasis, and EUS is the most sensitive imaging mod-
ality [0.34 (95% CI: 0.10-0.69)] with a specificity of 0.96
(95% CI: 0.87-0.99) in detecting peritoneal metastasis.
The strengths of this systematic review were its well-
defined search strategy, selection of study according to
the strict inclusion criteria, independent methodological
quality assessment by two reviewers and more valid sta-
tistical model for diagnostic meta-analysis in the pre-
sence of heterogeneity. Of course, our study was not
faultless. Firstly, some included studies had a low meth-
odological quality. For instance, the two eligible MRI
studies only included patients with advanced gastric
cancer, this might lead to bias by non-representative
patient spectrum. Additionally, the great mass of
included studies had a potential bias of partial verifica-
tion, which was interpreted as not all of the study group
receive confirmation of the diagnosis by the reference
standard. It was especially noted that all included studies
did not report the uninterpretable/intermediate test
results, which might lead to the biased assessment of
the test characteristics. Secondly, except for CT studies,
the number of eligible studies is less. Besides many clini-
cal characteristics of patients (such as Lauren classifica-
tion) and technology parameters of imaging (such as
slice Thickness and interslice gap of CT) were mixed or
missing in included studies, so we failed to perform sub-
group analysis or meta-regression, which might find out
other possible causes of heterogeneity. Thirdly, due to
f e we l i g i b l es t u d i e s ,w eo n l yu s e dt h ed a t ao fC Ti n
detecting liver metastasis to test publication bias, there-
fore potential bias might occur. Fourthly, heterogeneity
caused by threshold/cut off effect was present for EUS
in detecting peritoneal metastasis, thus we should inter-
preted the pooled results prudently.
DOR, which means the ratio of the odds of positive test
results in diseased group relative to the odds of positive
test results in non-diseased group, is considered as
another important indicator of test accuracy that com-
bines the data from sensitivity and specificity into a new
index [54]. The value of a DOR ranges from zero to infi-
nity, with higher value indicating higher accuracy.
A DOR of 1.0 shows that a test can not distinguish
between patients with the disease and those without it.
We found that CT seemed to be more helpful in the
Table 2 Characteristics of the five included EUC studies
Study
(year, reference)
County No. of
patients
Transducer
frequency
(MHz)
Interpreter(s) Reference standard
Ozmen 2003 [27] United
States
48 NCD NCD Histological examination
Chu 2004 [30] United
States
402 12 An author
of the study
Histopathologic examination
Tio 1990 [31] United
States
84 7.5 or 12 NCD Surgical and pathological examization.
Chen 2002 [32] United
States
65 7.5 or 12 An author
of the study
Surgical and pathological findings
Lee 2005 [33] United
Kingdom
301 7.5 or 12 Experienced
radiologists
Surgery, histopathology or cytology
NCD: not clearly described.
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DOR 251.14 (95% CI: 83.53-755.07) and 66.18 (95% CI:
27.28-160.53) respectively. Unlike traditional SROC plots,
HSROC curves was plotted based on hierarchical models
in our meta-analysis, which clearly presented the result
of a global summary of test performance, the 95% confi-
dence ellipse around the mean values of sensitivity and
specificity of radiographer reporting, as well as a 95%
prediction ellipse for individual value of sensitivity and
specificity.
Previous studies reported that sensitivity of US ranged
from 0.36-0.87 in detecting liver metastasis [22,25,27]
and 0.05-0.33 in detecting peritoneal metastasis [25,29].
Then most of these studies excluded patients with
obvious distant metastases, which might be the reason
of low sensitivity of US in detecting liver and peritoneal
Table 3 Characteristics of the twenty-two included CT studies
Study
(year,
reference)
County No. of
patients
Use of
intravenous
contrast
(dose)
Section
thickness
(mm), gap
(mm)
Interpreter(s) Reference standard
Kim
1997 [21]
South
Korea
95 NCD 10, 10 Two radiologists
independently
Surgical and pathological
findings
Stell
1996 [22]
United
Kingdom
103 NCD NCD Experienced personnel Histological examination
Asencio
1997 [23]
Germany 71 NCD NCD NCD Surgical and histologic
evaluation
Ozmen
2003 [27]
United
States
48 NCD NCD NCD Histological examination
Nozoe
1999 [28]
United
States
36 NCD NCD An experienced
gynecologist
Operation findings
Kayaalp
2002 [29]
United
Kingdom
118 NCD 10, 10 A consultant radiologist Histopathological examinations
Lim
2006 [34]
South
Korea
124 60% iodinated contrast
material (2 mL/kg)
1.0-1.5 or 3.0-
7.0, NCD
Three experienced
gastrointestinal
radiologists
Surgical and histopathologic
standards
Chen
2005 [36]
United
States
68 60% iodine
(maximum 150 mL)
7, NCD An abdominal radiologist Surgical and histological
classification
Chamadol
2008 [39]
Thailand 64 Iodinated contrast material
(100 mL)
8, NCD An experienced
radiologist
Surgical-pathologic results
Yajima
2006 [40]
United
States
413 Iodinated contrast material
(NCD)
10, NCD Expert radiologists Clinical, surgical reports,
histopathologic findings
Yun
2005 [41]
United
States
81 NCD
(2 mL/kg)
3-5, NCD NCD Histopathologic examination
Kim
2005 [43]
United
States
124 Iopromide (150 ml) 5.0, NCD Two experienced
gastrointestinal radiologists
Histopathologic analysis
D’Elia
2000 [44]
Germany 127 Non-ionic contrast medium
(200 ml)
10,10 Two radiologists Histopathologic staging
Adachi
1997 [45]
United
States
56 Loparimon or omnipaque
(100 ml)
NCD, NCD One radiologist Surgical and histological
diagnosis
Shinohara
2005 [46]
Japan 112 Non-ionic contrast medium
(100 ml)
2.5, 2.5 Two authors of the study Surgical and histological
diagnosis
Davies
1997 [47]
United
Kingdom
105 Ultravist
(150 ml)
10, 5 One radiologist TNM histopathological stage
Yan
2007 [48]
China 220 Non-ionic contrast medium
(1.5 ml/kg)
3.75-5, NCD Two radiologists Surgical and histological
diagnosis
Roic
1994 [49]
Slovenia 45 Ioxitalamate (100 ml) 8, NCD NCD Surgical and pathological
finding
Gamón
2002 [50]
Spain 50 non-ionic iodated contrast
medium (120 ml)
5, 4 A single experienced
radiologist
Surgical and pathological
diagnosis
Zhang
2002 [51]
China 43 Cardiografin (80-100 ml) 5-10, 5-10 Two radiologists Surgical and pathological
examination
Yan
2010 [52]
China 640 Iopromide
(180 ml)
5, 2.5 Two radiologists Surgical and pathological
findings
Pan
2010 [53]
China 350 Iopromide
(180 ml)
5, NR Two experienced physicians Surgical and pathological
findings
NCD: not clearly described.
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in assessing hepatic metastasis was as low as 0.54 (95%
CI: 0.34-0.73) with an acceptable specificity of 0.98 (95%
CI: 0.90-0.99), and the pooled sensitivity in detecting
peritoneal metastasis was 0.09 (95% CI: 0.03-0.21) with
a relatively high specificity of 0.99 (95% CI: 0.96-1.00).
This showed that US was more helpful in patients sus-
pected of liver or peritoneal metastases.
EUS was initially developed primarily to overcome the
limitations of abdominal ultrasonography in pancreas and
a number of studies provided evidences on the high diag-
nostic accuracy and important role of EUS in staging of
gastric cancer [55]. Compared with abdominal US, EUS
has the advantage of placing the transducer close to the
lesion without interference of bowel gas, bone or fat. How-
ever, EUS has an inherent disadvantage of operator depen-
dency, which was the same as abdominal US. Although it
is well suitable for the assessment of T staging, EUS has a
limited effect in the overall assessment of more distant
spread. Additionally, EUS is an invasive technique
requiring sedation which will cause possible sedation-
related complications [11]. Previous studies mainly focused
on the usefulness of EUS in the evaluation of local invasion
and LN staging [11,12]; but studies aiming at assessing the
liver and peritoneal metastases were few [30-33]. We did
not perform combined analysis using the data of EUS in
the evaluation of liver metastases in the case of only two
eligible studies. Although the result of our meta-analysis
indicated that EUS was the most sensitive imaging modal-
ity in detecting peritoneal metastasis, the combined sensi-
tivity was as low as 0.34 (95% CI: 0.10-0.69). This was
similar with another systematic review, which concluded
that EUS is not designed to look at distant metastasis [56].
It was reported that laparoscopy facilitated detection of
EUS or CT-occult micrometastases on the peritoneal sur-
face or in the liver [57], and identified EUS or CT-occult
metastatic disease in 23% to 37% of patients [24,58]. The
result suggested that laparoscopy should be integrated as
part of the recommended staging algorithm in the detec-
tion of liver and peritoneal metastases in aftertime.
Table 4 Characteristics of the two included MRI studies
Study County No. of
patients
Use of
intravenous
contrast
(dose)
Section
thickness
(mm),
gap
(mm)
Field
strength
(T), coil
type
Interpreter(s) Reference
Standard
Tang
2006
[37]
China 25 Gadolinium, 0.1 mmol/
kg
10, NCD 0.5, array body
coil
Two experienced MRI
specialists
Surgical and
histopathologic
examination
Li
2007
[38]
China 35 Gadolinium, 0.1 mmol/
kg
NCD,
NCD
1.5, Phased
array body
coil
Two experienced radiologists Surgical and
histopathologic
examination
NCD: not clearly described.
Table 5 Characteristics of the five included 18F-FDG PET studies
Study
(year, reference)
County No. of
patients
Time of
fasting
before
scanning
FDG dose,
time
interval
between
FDG
administration
and scanning
Attenuation
correction,
reconstruction
method
Interpreter(s) Reference standard
Lim 2006 [34] South
Korea
124 4h 370-555 MBq,
60 min
Yes, order
subset
expectation
maximization
Two experienced nuclear
medicine
physicians
Surgical and
histopathologic
standards
Yoshioka 2003 [35] United
States
20 4 h Mean 222 MBq,
30 min
Yes, NCD Three PET specialists CT, cytology,
and clinical course
Yoshioka 2003 [35] United
States
22 4 h Mean 222 MBq,
45 min
Yes, NCD Three PET specialists CT, cytology,
and clinical course
Chen 2005 [36] United
States
68 4 h 370-555 Mbq,
60 min
Yes, iterative Two experienced
nuclear medicine physicians
Surgical and histological
classification
Yun 2005 [41] United
States
81 4 h 370 MBq,
60 min
Yes, iterative Two experienced nuclear
medicine physicians
Histopathologic
examination
Yeung 1998 [42] United
States
23 6 h 370 MBq,
45 min to 1 h
Yes, NCD An experienced PET
reader
Histology, surgical findings,
clinical follow-up
NCD: not clearly described.
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wall and the adjacent tissue, but also the presence of dis-
tant metastases by providing rapid and high spatial reso-
lution imaging [21,59]. The sensitivity of CT in the
detection of liver metastasis ranged from 0.29-1.00 in
included studies [21-24,27-29,44-51,53], the cause of so
Table 6 Quality assessment of included studies
Imaging
modality
Study
(year, reference)
Criteria of quality assessment
123456789 1 0 1 1 1 2 1 3 1 4 T S
US and CT Kim 1997 [21] +++++++ + / - + / - + / - + / - + / - + / - + 2 2
US and CT Stell 1996 [22] + + + +/- + + + +/- +/- + +/- +/- +/- + 22
US and CT Asencio 1997 [23] + + + +/- + + + - +/- +/- +/- +/- +/- - 18
US Possik 1986 [24] + + + +/- - + + - +/- +/- +/- +/- +/- - 16
US Derchi 1983 [25] + + + +/- - - + + +/- + +/- +/- +/- + 19
US Liao 2004 [26] + - + +/- - - + + +/- +/- +/- +/- +/- - 14
US, EUS and CT Ozmen 2003 [27] + + + +/- - - + - - + + +/- +/- + 17
CT Nozoe 1999 [28] - + + +/- - - + +/- +/- +/- +/- +/- +/- + 15
US and CT Kayaalp 2002 [29] + - + +/- +/- - + +/- +/- +/- +/- +/- +/- + 16
EUS Chu 2004 [30] ++++++++ + / - ++ + / - + / - + 2 5
EUS Tio 1990 [31] - +/- + + + - + + +/- + +/- +/- +/- + 19
EUS Chen 2002 [32] +/- +/- + + - - + + +/- +/- +/- +/- +/- + 17
EUS Lee 2005 [33] + - +/- - - + +/- + +/- + + +/- +/- + 17
CT and PET Lim 2006 [34] + - + +/- - - + + + +/- +/- +/- +/- + 17
PET Yoshioka 2003 [35] +/- - +/- +/- +/- +/- + + +/- + +/- +/- +/- + 17
CT and PET Chen 2005 [36] + +/- + +/- +/- +/- ++++ + / - + / - + / - + 2 1
MRI Tang 2006 [37] - +/- + + +/- +/- + + +/- + +/- +/- +/- + 19
MRI Li 2007 [38] - +/- + + +/- +/- + + +/- + +/- +/- +/- - 15
CT Chamadol 2008 [39] +/- +/- + - - - + + +/- + +/- + +/- + 17
CT Yajima 2006 [40] - +/- + +/- - +/- + + +/- + +/- +/- +/- + 17
CT and PET Yun 2005 [41] + +/- + +/- - - +/- +/- +/- + + +/- +/- + 17
PET Yeung 1998 [42] +/- +/- + +/- - - + + +/- +/- +/- +/- +/- + 16
CT Kim 2005 [43] +/- +/- + + - - + + +/- + +/- +/- +/- + 18
CT D’Elia 2000 [44] +/- +/- + +/- - - + + +/- +/- +/- +/- +/- + 16
CT Adachi 1997 [45] - +/- + +/- + +/- + +/- +/- +/- +/- +/- +/- + 17
CT Shinohara 2005 [46] - +/- ++++++ + / - + + / - + / - + / - + 2 1
CT Davies 1997 [47] +/- +/- ++++++++ + / - + / - + / - + 2 3
CT Yan 2007 [48] + - + + - - + +/- +/- + +/- +/- +/- + 17
CT Roic 1994 [49] +/- - + +/- - + + +/- +/- +/- +/- +/- +/- - 14
CT Gamón 2002 [50] +/- - + + +/- +/- + + +/- +/- +/- +/- +/- + 18
CT Zhang 2002 [51] + - + +/- +/- +/- + + +/- +/- +/- +/- +/- + 18
CT Yan 2010 [52] + +/- ++++++ + / - + + / - + / - + / - + 2 3
CT Pan 2010 [53] + +/- + +/- + + + +/- +/- +/- +/- +/- +/- + 20
TS: total score.
Table 7 Spearman correlation coefficient Logit
(sensitivity) vs Logit (1- specificity)
Outcomes Liver metastasis Peritoneal metastasis
US CT PET US EUS CT PET
Scc 0.643 -0.143 0.400 0.200 1.000 0.329 0.200
p-value 0.119 0.598 0.600 0.800 0.000 0.297 0.800
Scc: Spearman correlation coefficient.
Table 8 Results of Cochrane-Q test
Outcomes Liver metastasis Peritoneal metastasis
US CT PET US EUS CT PET
Sen Q-value 23.87 40.96 7.95 7.24 FC 82.07 6.12
p-value 0.00 0.00 0.09 0.12 FC 0.00 0.19
Spe Q-value 153.95 77.99 19.61 5.34 FC 57.09 34.25
p-value 0.00 0.00 0.00 0.25 FC 0.00 0.00
DOR Q-value 88.72 40.12 30.55 18.90 FC 23.50 44.18
p-value 0.00 0.00 0.00 0.00 FC 0.05 0.00
Sen: sensitivity; Spe: Specificity; DOR: diagnostic odds ratio; FC: failed to
calculate.
The results were calculated by using the midas command in stata software.
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Page 8 of 14wide an interval possibly was the use of different tomo-
graphy techniques in included studies, for example some
researchers used single-detector row CT but others used
multi-detector CT (MDCT), which can overcome the low
scanning speed of single-detector row CT by its ability to
make thinner sections in a shorter time. In our study we
found that the diagnostic accuracy of CT was moderate
with a pooled sensitivity of 0.74 (95% CI: 0.59-0.85) in
the detection of liver metastasis. Additionally, the result
of meta-analysis indicated that the sensitivity of CT in
detecting peritoneal metastasis was very low [0.33 (95%
CI: 0.16-0.56)], which supported the viewpoint that peri-
toneal metastasis was one of the limitations of CT in pre-
dicting the stage of gastric cancer preoperatively [21].
Newer MDCT technology (such as the application of
128- to 256-section MDCT scanners or dual-source tech-
nology) was reckoned to improve diagnostic performance
with a spatial resolution of 5 mm or less in diameter [12].
Compared with CT, PET has an advantage of providing
functional information. Currently PET is not only being
evaluated as a staging tool for gastric cancer, but also
useful for monitoring tumor recurrence and response to
neoadjuvant therapy [59,60]. Although some researchers
reported that PET had utilities in detecting liver and peri-
toneal metastases (the sensitivity could achieve 100% and
57% respectively) [42,61], we did not found that
18F-FDG
PET had advantages over CT in the assessment of liver
and peritoneal metastases in our meta-analysis. Possible
reasons for the reported low to moderate sensitivity of
FDG-PET is lack of detailed anatomic information in the
area of significant tracer uptake and its limited resolu-
tion. It was reported that combining both PET and CT
(PET/CT) has demonstrated further improvements in
diagnostic accuracy recently [59]. The method unites the
high anatomic spatial information from CT with the
functional information offered by PET, and has a benefit
of the rapid CT based attenuation correction of PET.
This can decrease scanning time and increase the degree
of comfort. Pyrimidine analog 3-deoxy-3-18F-fluorothy-
midine (
18F-FLT), a new stable PET tracer was used for
improving the diagnostic accuracy lately. It was reported
that
18F-FLT had a higher sensitivity than
18F-FDG PET
in the detection of locally advanced gastric cancer [62].
However, whether this imaging modality will improve the
diagnostic accuracy of liver and peritoneal metastases
needs further investigation.
MRI has evolved to be an important imaging method
for detection and characterization of most of common
diseases of the abdomen including gastric cancer [63,64].
Advantages of MRI over CT include the ability of gener-
ating significantly greater soft tissue contrast resolution,
and the ability of removing the risk of iodinated contrast-
induced nephropathy or ionizing radiation [64]. However
only two eligible MRI studies [37,38] were identified in
our review, and all from China, therefore the data were
not combined. The two studies found that MRI had both
high sensitivity and specificity in detecting liver metasta-
sis. Some researchers reported that diffusion-weighted
(DW) MRI was more sensitive than CT in detecting liver
and peritoneal metastases, and functional parameters
such as apparent diffusion coefficient (ADC) could moni-
tor the response to neoadjuvant chemotherapy [65].
These results seemed inspiring, whereas the sample size
was small and methodological quality was moderate.
Therefore more MRI (especially DW-MRI) studies focus-
ing on evaluating the liver and peritoneal metastases are
urgently needed in future.
Conclusions
Although the result of our meta-analysis showed that CT
was the most sensitive imaging method with a high rate
Table 9 Results of diagnostic value of imaging
Imaging modality Sen (95%CI) Spe (95%CI) DOR (95%CI)
Liver metastasis US 0.54
(0.34-0.73)
0.98
(0.90-0.99)
50.25
(13.48-187.32)
CT 0.74
(0.59-0.85)
0.99
(0.97-1.00)
251.14
(83.53-755.07)
PET 0.70
(0.36-0.90)
0.96
(0.81-0.99)
56.46
(8.47-376.23)
Peritoneal metastasis US 0.09
(0.03-0.21)
0.99
(0.96-1.00)
10.63
(1.54-73.36)
EUS 0.34
(0.10-0.69)
0.96
(0.87-0.99)
13.07
(6.42-26.62)
CT 0.33
(0.16-0.56)
0.99
(0.98-1.00)
66.18
(27.28-160.53)
PET 0.28
(0.17-0.44)
0.97
(0.83-1.00)
12.49
(2.22-70.10)
Sen: sensitivity; Spe: Specificity; DOR: diagnostic odds ratio; CI: confidence
interval.
The results were combined using the metandi command (based on bivariate
model) in stata software.
Table 10 Results of EUS and MRI in the detection of liver metastases
Imaging modality Study ID Sen (95% CI) Spe (95% CI) DOR (95% CI)
EUS Ozmen 2003 [27] 0.00 (0.00-0.46) 0.86 (0.71-0.95) 0.43 (0.02-8.63)
Tio 1990 [31] 0.67 (0.09-0.99) 0.95 (0.88-0.99) 38.50 (2.85-519.60)
MRI Tang 2006 [37] 1.00 (0.40-1.00) 1.00 (0.89-1.00) 567.00 (9.95-32300.14)
Li 2007 [38] 1.00 (0.40-1.00) 1.00 (0.87-1.00) 477.00 (8.35-27250.55)
Sen: sensitivity; Spe: Specificity; DOR: diagnostic odds ratio; CI: confidence interval.
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Figure 2 HSROC curve of US for the detection of liver
metastases.
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Figure 5 HSROC curve of CT for the detection of liver
metastases.
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Page 10 of 14of specificity in detecting hepatic metastasis, and EUS
was the most sensitive imaging modality with a relatively
low rate of specificity (compared with the three other
imaging methods) in detecting peritoneal metastasis, we
concluded that US, EUS, CT and
18F-FDG PET did not
obtain consistently high sensitivity and specificity in
detecting liver and peritoneal metastases in patients with
gastric cancer. More attention should be paid to laparo-
scopy, PET/CT, DW-MRI, as well as new PET tracers
such as
18F-FLT in the detection of liver and peritoneal
metastases of gastric cancer in future.
Appendix
Midas: is a comprehensive program of statistical and
graphical routines for undertaking meta-analysis of
diagnostic test performance in Stata. It facilitates
exploratory analysis of heterogeneity, publication and
other precision-related biases.
Metandi: The metandi command display the results in
two alternative parameterizations and produce a custo-
mizable plot. It also displays some familiar summary
measures (such as sensitivity and specificity). The com-
mand requires either Stata 10 or above (which has the
new command xtmelogit), or Stata 8.2 or above with
gllamm installed.
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Figure 6 HSROC curve of CT for the detection of peritoneal
metastases.
0
.
2
.
4
.
6
.
8
1
0 .2 .4 .6 .8 1
Specificity
Study estimate Summary point
HSROC curve 95% confidence
region
95% prediction
region
Figure 7 HSROC curve of 18F-FDG PET for the detection of
liver metastases.
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Figure 8 HSROC curve of 18F-FDG PET for the detection of
peritoneal metastases.
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Page 11 of 141. Midas command for testing the heterogeneity of
sensitivity and specificity:
midas tp fp fn tn, texts(0.60) bfor(dss) ford fors
2. Midas command for testing the heterogeneity of
DOR:
midas tp fp fn tn, texts(0.60) bfor(dlor) ford fors
3. Metandi command for the pooled analysis of sensi-
tivity, specificity and DOR, and for plotting the HSROC
curves:
metandi tp fp fn tn, plot
4. Midas command for testing publication bias:
midas tp fp fn tn, pubbias
(tp: true positives, fp: false positives, fn: false negatives,
tn: true negatives)
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